Gladius Pharmaceuticals Corp — Form D
Gladius Pharmaceuticals Corp of WILMINGTON, DE, a company, filed a Form D exempt-offering notice with the SEC on 2018-11-28. The offering totals $3.0M, of which $3.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-11-28
- Form: D
- Accession: 0001646819-18-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.0M
- Amount sold: $3.0M
- Investors: 5
- Date of first sale: 2018-11-14
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-326665
Issuer
- Name: Gladius Pharmaceuticals Corp
- CIK: 0001646819
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON, DE, 19808
- Phone: 514-213-4456
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Nathalie Chauret | Director | Wilmington, DE |
| Jens Eckstein | Director | Cambridge, MA |
| Daniel Hetu | Director | Montreal, A8 |
| Larry Sutton | Director | Wilmington, DE |
| Michael Atkin | Executive Officer | Kirkland, A8 |
| Michael Atkin | Director | Kirkland, A8 |
Other filings by this issuer (1)
More